Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial

MLA

Ka Jia Cao, et al. “Concurrent Chemoradiotherapy with Nedaplatin versus Cisplatin in Stage II-IVB Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Randomised Phase 3 Trial.” The Lancet. Oncology, vol. 19, no. 4, Nov. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d38d04b52fddd500685cd18c4c959eee&authtype=sso&custid=ns315887.

APA

Ka Jia Cao, Yuanhong Gao, Ming-Yuan Chen, Dong Ping Chen, Bin Qi, Shan Shan Guo, Wei Xiong Xia, Qing Nan Tang, Ling Guo, Dong Hua Luo, Hao Yuan Mo, Lin Quan Tang, Pan Wang, Xiang Guo, Xing Lv, Jin Jie Yan, Ying Huang, Pei Yu Huang, Xiao Yun Li, … Li Ting Liu. (2017). Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. The Lancet. Oncology, 19(4).

Chicago

Ka Jia Cao, Yuanhong Gao, Ming-Yuan Chen, Dong Ping Chen, Bin Qi, Shan Shan Guo, Wei Xiong Xia, et al. 2017. “Concurrent Chemoradiotherapy with Nedaplatin versus Cisplatin in Stage II-IVB Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Randomised Phase 3 Trial.” The Lancet. Oncology 19 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d38d04b52fddd500685cd18c4c959eee&authtype=sso&custid=ns315887.